Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oncternal Therapeutics : Brookline Capital Initiates Coverage on Oncternal Therapeutics With Buy Rating, $16 Price Target

03/30/2021 | 09:34am EST


© MT Newswires 2021
All news about ONCTERNAL THERAPEUTICS, INC.
01/25ONCTERNAL THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/20Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies..
GL
01/20Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies..
GL
01/05AFTER HOURS WATCH LIST SCORECARD : Wejo, onct, swim
MT
01/05ONCTERNAL THERAPEUTICS : Corporate Presentation, January 2022
PU
01/04MT NEWSWIRES AFTER HOURS WATCH LIST : Wejo, onct, swim
MT
01/04Oncternal Therapeutics Finalizes Study Design for Late-Stage Mantle Cell Lymphoma Trial..
MT
01/04Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Stud..
AQ
01/04Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrationa..
CI
2021ONCTERNAL THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
Analyst Recommendations on ONCTERNAL THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 5,08 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 94,4 M 94,4 M -
Capi. / Sales 2021 18,6x
Capi. / Sales 2022 37,5x
Nbr of Employees 13
Free-Float 87,7%
Chart ONCTERNAL THERAPEUTICS, INC.
Duration : Period :
Oncternal Therapeutics, Inc. Technical Analysis Chart | ONCT | US68236P1075 | MarketScreener
Technical analysis trends ONCTERNAL THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,91 $
Average target price 15,50 $
Spread / Average Target 712%
Managers and Directors
James B. Breitmeyer President, Chief Executive Officer & Director
Richard Glenn Vincent Chief Financial Officer, Secretary & Treasurer
David F. Hale Director
Rajesh Krishnan Chief Technology Officer
Gunnar F. Kaufmann Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCTERNAL THERAPEUTICS, INC.-15.86%95
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842